NCT04799054View on ClinicalTrials.gov

A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

188

Participants

Timeline

Start Date

March 18, 2021

Primary Completion Date

January 31, 2026

Study Completion Date

March 31, 2026

Conditions
Advanced Solid TumorLocally Advanced Solid TumorMetastatic Solid TumorHead and Neck Squamous Cell Carcinoma HNSCCHPV-associated CancersNeoadjuvant MelanomaNeoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)
Interventions
DRUG

TransCon TLR7/8 Agonist

TransCon TLR7/8 Agonist will be administered as an IT injection

DRUG

Pembrolizumab

Pembrolizumab will be administered IV

Trial Locations (49)

112

Ascendis Investigational Site, Taipei

404

Ascendis Investigational Site, Taichung

704

Ascendis Investigational Site, Tainan City

1066

Ascendis Investigational Site, Amsterdam

2500

Ascendis Pharma Investigational Site, Wollongong

3199

Ascendis Pharma Investigational Site, Frankston

5042

Ascendis Investigational Site, Bedford Park

13620

Ascendis Investigational Site, Seongnam

15232

Ascendis Pharma Investigational Site, Pittsburgh

16247

Ascendis Investigational Site, Suwon

16499

Ascendis Investigational Site, Suwon

22031

Ascendis Pharma Investigational Site, Fairfax

28027

Ascendis Investigational Site, Madrid

28040

Ascendis Investigational Site, Madrid

28041

Ascendis Investigational Site, Madrid

28050

Ascendis Investigational Site, Madrid

29010

Ascendis Investigational Site, Málaga

30120

Ascendis Investigational Site, Murcia

31008

Ascendis Investigational Site, Pamplona

33612

Ascendis Investigational Site, Tampa

37920

Ascendis Pharma Investigational Site, Knoxville

40202

Ascendis Pharma Investigational Site, Louisville

40705

Ascendis Investigational Site, Taichung

41009

Ascendis Investigational Site, Seville

42601

Ascendis Investigational Site, Dalseo-gu

44106

Ascendis Pharma Investigational Site, Cleveland

44718

Ascendis Pharma Investigational Site, Canton

45219

Ascendis Pharma Investigational Site, Cincinnati

46009

Ascendis Investigational Site, Valencia

49201

Ascendis Investigational Site, Seogu

49267

Ascendis Investigational Site, Seogu

52242

Ascendis Pharma Investigational Site, Iowa City

60637

Ascendis Pharma Investigational Site, Chicago

75235

Ascendis Investigational Site, Dallas

75390

Ascendis Investigational Site, Dallas

77030

Ascendis Investigational Site, Houston

90067

Ascendis Investigational Site, Los Angeles

91010

Ascendis Pharma Investigational Site, Duarte

92868

Ascendis Investigational Site, Orange

94158

Ascendis Pharma Investigational Site, San Francisco

3015 GD

Ascendis Investigational Site, Rotterdam

06591

Ascendis Investigational Site, Seocho-gu

03722

Ascendis Investigational Site, Seoul

05505

Ascendis Investigational Site, Seoul

06273

Ascendis Investigational Site, Seoul

08003

Ascendis Investigational Site, Barcelona

08028

Ascendis Investigational Site, Barcelona

08035

Ascendis Investigational Site, Barcelona

08908

Ascendis Investigational Site, Barcelona

All Listed Sponsors
lead

Ascendis Pharma Oncology Division A/S

INDUSTRY